Biohaven Pharmaceuticals Revenue and Competitors

Claim your profile

New Haven, CT USA

Location

$443.7M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Biohaven Pharmaceuticals's estimated annual revenue is currently $307.6M per year.(i)
  • Biohaven Pharmaceuticals received $143.7M in venture funding in December 2018.
  • Biohaven Pharmaceuticals's estimated revenue per employee is $217,239
  • Biohaven Pharmaceuticals's total funding is $443.7M.
  • Biohaven Pharmaceuticals's current valuation is $8B. (January 2022)

Employee Data

  • Biohaven Pharmaceuticals has 1416 Employees.(i)
  • Biohaven Pharmaceuticals grew their employee count by 18% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$9.8M703%N/AN/A
#2
$24.3M15723%N/AN/A
#3
$4.5M29-9%N/AN/A
#4
$1.1M775%N/AN/A
#5
$16.3M1283%N/AN/A
#6
$3.6M23-42%N/AN/A
#7
$7.4M48N/AN/AN/A
#8
$13.8M8922%N/AN/A
#9
$15.1M412-2%$330.5MN/A
#10
$29.8M19251%N/AN/A

Biohaven is engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. Biohaven obtained licenses from Yale University School of Medicine and Massachusetts General Hospital regarding intellectual property relating to the use of certain glutamate modulating agents in the treatment of neuropsychiatric disorders. The mission of the company is to exploit advances over the past decade in the understanding of glutamate mechanisms involved in a variety of diseases. The company's first drug candidate is being developed for orphan neurological disorders as well as treatment-resistant anxiety and depression. Biohaven has assembled a team of experts who have extensive experience in the development of therapeutic agents in this area and also comprise the originators at Yale University who discovered the therapeutic potential of glutamate modulation in anxiety and depression. Team members have designed and executed successful development programs testing a variety of agents in affective disorders, leading to first-cycle FDA approvals and successful commercialization.

keywords:N/A

$443.7M

Total Funding

1416

Number of Employees

$307.6M

Revenue (est)

18%

Employee Growth %

$8B

Valuation

N/A

Accelerator

Biohaven Pharmaceuticals News

2022-04-19 - Biohaven migraine drug partnered with Pfizer lands twin ...

The European Commission approved Biohaven Pharmaceuticals migraine drug rimegepant. While the regulatory decision marks another milestone for...

2022-04-19 - Pfizer and Biohaven's VYDURA® (Rimegepant) Granted First ...

Biohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of...

2022-04-19 - Pfizer and Biohaven clinch migraine approval in Europe, beating AbbVie to key market

Looking to reach patients with a wide range of migraine symptoms in Europe, Pfizer and Biohaven are first on the scene with an oral CGRP...

2021-11-09 - Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States

NEW HAVEN, Conn. and NEW YORK, Nov. 9, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval. Rimegepant is commerc ...

2021-11-02 - Nine Line Apparel and Biohaven's Nurtec ODT Set to Honor World War II Veterans Ahead of 80th Anniversary at Phoenix Raceway

MOORESVILLE, N.C., Nov. 2, 2021 /PRNewswire/ -- Rick Ware Racing (RWR) has joined forces once again with Nine Line Apparel and Biohaven Pharmaceuticals' Nurtec® ODT (rimegepant) to pay tribute and honor the upcoming 80th Anniversary of the Attack on Pearl Harbor this weekend at Phoenix Raceway f ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$725M2877N/AN/A
#2
$892.9M30374%N/A
#3
$1568.3M414925%N/A
#4
$907.7M451611%N/A
#5
$1200.8M4765-7%N/A

Biohaven Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2017-03-08$80.0MSecondVenrockArticle
2018-06-20$150.0MUndisclosedRoyalty PharmaArticle
2018-12-13$143.7MUndisclosedGoldman Sachs & Co. LLCArticle